Diabetic macular edema is a complication that develops from diabetic retinopathy, a widespread consequence of diabetes and a ...

Genentech opposes the use of Avastin to treat eye diseases such as macular degeneration, noting that the drug isn't approved by regulators for this purpose. Genentech has a similar drug ...

As Avastin needs to be removed from its original vials and introduced into single-use syringes suitable for injection into the eye, Novartis and Roche have long argued that the repackaging ...

Seven months after the FDA approved the reintroduction of Roche's eye implant Susvimo, the US agency has expanded its approved use to include treatment for diabetic macular edema, the primary ...

Detailed price information for Roche Holdings Ltd ADR (RHHBY) from The Globe and Mail including charting and trades.

On a macro basis, in the first quarter of 2025, the overall size of the branded anti-VEGF category contracted due to an increase in the usage of low-cost off-label repackaged Avastin, likely ...

Sales in the Pharmaceuticals Division were up 8% in the first quarter to CHF 11.9 billion, owing to strong growth in demand for key drugs like Phesgo (breast cancer), Vabysmo (severe eye diseases ...

Avastin needs to be diluted and repackaged before it can be used in the eye, with dosing every four to six weeks, and is much less expensive. That hasn’t stopped the branded wet AMD drugs from ...